Brant Peterson, Vice President & Fellow at Valo Health, joins Data in Biotech to explore how his team leverages real-world data, genetic insights, and machine learning to de-risk drug discovery. From building causal DAGs to identifying patient subtypes in neurodegenerative diseases like Parkinson’s, this episode dives deep into a patient-first, data-driven approach to biomedical innovation.

What You'll Learn in This Episode:

>> How Valo Health uses real-world evidence and EHR data to prioritize drug targets earlier in the development pipeline.

>> Why integrating wet lab experiments and causal DAGs accelerates therapeutic validation.

>> The importance of genetic pleiotropy and Mendelian randomization in refining disease hypotheses.

>> How Valo Health identifies high-impact patient subgroups in neurodegenerative diseases like Parkinson’s and Alzheimer’s.

>> Where machine learning models succeed and fall short, in uncovering mechanisms of disease from sparse longitudinal data.

Meet Our Guest

Brant Peterson is Vice President & Fellow in Data Science at Valo Health. He brings deep expertise in genetics, computational biology, and biomedical innovation. Formerly a Distinguished Data Scientist at Valo and Computational Biologist at Novartis, Brant focuses on leveraging patient-centric data to drive causal discovery in drug development.

About The Host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

Sponsor: CorrDyn, a data consultancy
Connect with Brant Peterson on LinkedIn

Connect with Us:

Follow the podcast for more insightful discussions on the latest in biotech and data science.
Subscribe and leave a review if you enjoyed this episode!
Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Brant Peterson on Valo Health’s patient-first approach to drug discovery